STOCK TITAN
  1. Home
  2. News
  3. KRBP

Kiromic BioPharma Inc - KRBP STOCK NEWS

Welcome to our dedicated news page for Kiromic BioPharma (Ticker: KRBP), a resource for investors and traders seeking the latest updates and insights on Kiromic BioPharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kiromic BioPharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kiromic BioPharma's position in the market.

News
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
Rhea-AI Summary
Kiromic BioPharma reports consistent favorable safety, tolerability, and efficacy in Deltacel-01 clinical trial for the first three patients. The company's allogeneic Gamma Delta T-cell therapy shows stable disease in patients with stage 4 metastatic non-small cell lung cancer. Kiromic plans to apply for FDA Fast Track Designation based on positive preliminary results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
clinical trial
-
News
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
Rhea-AI Summary
Kiromic BioPharma, Inc. reports positive early efficacy results in the Deltacel-01 Phase 1 clinical trial for treating stage 4 metastatic non-small cell lung cancer. The Safety Monitoring Committee recommends maintaining the initial cell dose level for the next cohort of patients, indicating promising safety, tolerability, and anti-tumor activity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
clinical trial
-
News
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial
Rhea-AI Summary
Kiromic BioPharma, Inc. (KRBP) reports positive early efficacy results in the Deltacel-01 Phase 1 clinical trial for treating stage 4 metastatic non-small cell lung cancer. The therapy, Deltacel™ (KB-GDT-01), showed tumor stabilization and brain metastases disappearance in the second patient. The treatment demonstrated favorable safety and tolerability, with stable disease status confirmed by CT scan. The patient's brain metastases completely resolved after treatment, indicating promising potential for Deltacel as a therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.94%
Tags
clinical trial
News
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
Rhea-AI Summary
Kiromic BioPharma, Inc. enrolls third patient in Deltacel-01 trial for NSCLC treatment, expanding trial sites and expecting preliminary results soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.4%
Tags
clinical trial
-
News
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
Rhea-AI Summary
Kiromic BioPharma, Inc. (KRBP) announces participation in OTC Markets’ Life Science Investor Forum in a Fireside Chat format. The event will feature CEO Pietro Bersani, CFO Brian Hungerford, and CSO/Interim Operations Officer Leonardo Mirandola. Investors can engage in real-time Q&A and access the archived webcast post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.78%
Tags
conferences
-
News
Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months
Rhea-AI Summary
Kiromic BioPharma, Inc. announces positive clinical findings in Phase 1 trial of Deltacel™ for Non-Small Cell Lung Cancer treatment. First patient shows tumor reduction and metabolic decrease. Second patient completes treatment, third patient dosed. Encouraging results pave the way for further trials and potential treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38.49%
Tags
clinical trial
News
Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer
Rhea-AI Summary
Kiromic BioPharma, Inc. reports positive early efficacy results from the Phase 1 Deltacel-01 clinical trial for treating stage 4 metastatic non-small cell lung cancer (NSCLC). The therapy, Deltacel, has shown favorable evidence in controlling the growth of NSCLC and is well-tolerated. The first patient enrolled in the trial experienced disease stabilization at six weeks, indicating a preliminary progression-free survival of one and one-half months. Kiromic plans to provide updates as more data becomes available, emphasizing the potential of Deltacel in treating NSCLC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18%
Tags
clinical trial
-
News
Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial
Rhea-AI Summary
Kiromic BioPharma, Inc. (KRBP) reports favorable safety and tolerability from the first patient 23 days after Deltacel™ infusion in the Phase 1 clinical trial for treatment of stage 4 metastatic non-small cell lung cancer (NSCLC) at Beverly Hills Cancer Center. The initial safety profile indicates no adverse events, and the company expects to report preliminary efficacy results by the end of January 2024. Company executives will be available to meet with investment professionals in San Francisco during the 42nd Annual J.P. Morgan Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20%
Tags
clinical trial
-
News
Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer
Rhea-AI Summary
Kiromic BioPharma, Inc. (KRBP) announces the initiation of the Deltacel-01 clinical trial for the treatment of stage 4 metastatic non-small cell lung cancer. Initial tolerability and safety data from the first patient is expected by year-end, with preliminary efficacy results by the end of January 2024. The trial will start enrolling patients at two additional clinical sites in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.7%
Tags
clinical trial
News
Kiromic BioPharma Announces Uplisting to OTCQB Market
Rhea-AI Summary
Kiromic BioPharma, Inc. (KRBP) Announces Uplisting to OTCQB Venture Market, Enhancing Market Visibility and Trading Liquidity. The company's proprietary DIAMOND® AI platform is utilized for developing cell therapies with a focus on immuno-oncology. The uplisting reflects Kiromic's commitment to transparency and increased market visibility, providing enhanced opportunities for shareholders and exposure to a broader range of investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12%
Tags
none
Stock KRBP logo
Kiromic BioPharma Inc

OTC:KRBP

KRBP Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

KRBP Stock Data

3.79M
1.01M
10.91%
3.89%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Houston

About KRBP

kiromic exists to create a robust diagnostic and therapeutic program for solid tumors and hematologic malignancies based on its portfolio of patented cancer-associated biomarkers and small molecules. kiromic aims to develop clinical diagnostic tools for rapid detection of cancer-associated antigens, which may translate into earlier diagnosis and accurate monitoring of response to cancer treatments. our cancer-associated biomarkers also allow for the design and development of personalized, cancer-specific targeted immunotherapy strategies that may improve patient outcomes and result in less suffering and longer survival times.